Sarepta Therapeutics, Inc. (SRPT) Upgraded to Buy at BidaskClub
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Friday.
Other equities research analysts also recently issued reports about the company. J P Morgan Chase & Co set a $42.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Saturday, March 11th. Oppenheimer Holdings, Inc. set a $76.00 price objective on Sarepta Therapeutics and gave the company a “buy” rating in a report on Sunday, March 26th. Piper Jaffray Companies set a $43.00 price objective on Sarepta Therapeutics and gave the company a “buy” rating in a report on Thursday, May 18th. Vetr downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 price objective on the stock. in a report on Monday, May 15th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a report on Thursday. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $59.95.
Shares of Sarepta Therapeutics (SRPT) traded down 1.30% during mid-day trading on Friday, reaching $35.02. The company’s stock had a trading volume of 2,047,642 shares. Sarepta Therapeutics has a 12 month low of $16.52 and a 12 month high of $63.73. The stock’s market capitalization is $1.92 billion. The company has a 50 day moving average price of $32.66 and a 200 day moving average price of $31.47.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, April 27th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.12. The firm had revenue of $16.34 million for the quarter, compared to analyst estimates of $13.80 million. During the same period last year, the business earned ($1.15) earnings per share. The firm’s quarterly revenue was up 163300.0% compared to the same quarter last year. On average, equities research analysts anticipate that Sarepta Therapeutics will post ($0.65) earnings per share for the current fiscal year.
WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/23/sarepta-therapeutics-inc-srpt-upgraded-to-buy-at-bidaskclub.html.
A number of hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $645,000. Raymond James Financial Services Advisors Inc. raised its stake in Sarepta Therapeutics by 417.6% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 8,063 shares of the biotechnology company’s stock worth $221,000 after buying an additional 10,602 shares in the last quarter. Allianz Asset Management AG acquired a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $1,675,000. Pacad Investment Ltd. acquired a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $255,000. Finally, First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 0.3% in the fourth quarter. First Allied Advisory Services Inc. now owns 9,026 shares of the biotechnology company’s stock worth $248,000 after buying an additional 26 shares in the last quarter. 73.49% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.